Endocrine Manipulation in Male Infertility

Urologic Clinics of North America

Volumn 35, Issue 2, 2008, Pages 303-318

  Kim, Howard H ^a,b   Schlegel, Peter N ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BUSERELIN ACETATE; CLOMIFENE CITRATE; CYCLOPHOSPHAMIDE; GONADORELIN; GONADOTROPIN RECEPTOR; MEDROXYPROGESTERONE ACETATE; MESTEROLONE; OXYTOCIN; TAMOXIFEN CITRATE; TESTOLACTONE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ANDROGEN RELEASE; AUTOSOMAL DOMINANT INHERITANCE; CRYPTORCHISM; DNA DETERMINATION; HORMONAL THERAPY; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KALLMANN SYNDROME; MALE INFERTILITY; OLIGOSPERMIA; PRIORITY JOURNAL; REVIEW; SPERMATOGENESIS;

ANDROGENS; AROMATASE INHIBITORS; ESTROGEN RECEPTOR MODULATORS; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; INFERTILITY, MALE; MALE;

EID: 41949141353     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2008.01.003     Document Type: Review

References (130)

1. Brugh III V.M., Maduro M.R., and Lamb D.J. Genetic disorders and infertility. Urol Clin North Am 30 1 (2003) 143-152
2. Griffin J.E. Androgen resistance-the clinical and molecular spectrum. N Engl J Med 326 9 (1992) 611-618
3. Sigman M., and Jarow J.P. Endocrine evaluation of infertile men. Urology 50 5 (1997) 659-664
4. Dunphy B.C., Kay R., Barratt C.L., et al. Is routine examination of the male partner of any prognostic value in the routine assessment of couples who complain of involuntary infertility?. Fertil Steril 52 3 (1989) 454-456
5. Kolettis P.N., and Sabanegh E.S. Significant medical pathology discovered during a male infertility evaluation. J Urol 166 1 (2001) 178-180
6. Nieschlag E. Classification of andrological disorders. In: Nieschlag E., Behre H., and Nieschlag S. (Eds). Andrology: male reproductive health and dysfunction. 2nd edition (1997), Springer-Verlag, Berlin 83-87
7. Guzick D.S., Overstreet J.W., Factor-Litvak P., et al. Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med 345 19 (2001) 1388-1393
8. Brugh III V.M., Matschke H.M., and Lipshultz L.I. Male factor infertility. Endocrinol Metab Clin North Am 32 3 (2003) 689-707
9. Adamopoulos D.A. Present and future therapeutic strategies for idiopathic oligozoospermia. Int J Androl 23 6 (2000) 320-331
10. Cadman S.M., Kim S.H., Hu Y., et al. Molecular pathogenesis of Kallmann's syndrome. Horm Res 67 5 (2007) 231-242
11. Duke V.M., Winyard P.J., Thorogood P., et al. KAL, a gene mutated in Kallmann's syndrome, is expressed in the first trimester of human development. Mol Cell Endocrinol 110 1-2 (1995) 73-79
12. Haidl G. Management strategies for male factor infertility. Drugs 62 12 (2002) 1741-1753
13. Zwart-van Rijkom J.E., Broekmans F.J., and Leufkens H.G. From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study. Hum Reprod 17 4 (2002) 857-865
14. Daya S., Gunby J., Hughes E.G., et al. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertil Steril 64 2 (1995) 347-354
15. Agrawal R., Holmes J., and Jacobs H.S. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril 73 2 (2000) 338-343
16. Balasch J. The challenge of meta-analysis and the need to register clinical trials. Fertil Steril 74 2 (2000) 420 author reply 421-2
17. Daya S. The challenge of meta-analysis and the need to register clinical trials. Fertil Steril 74 2 (2000) 420-422
18. Van Wely M., Westergaard L.G., Bossuyt P.M., et al. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 1 (2003) CD003973
19. Weiss J., Axelrod L., Whitcomb R.W., et al. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 326 3 (1992) 179-183
20. Latronico A.C., Anasti J., Arnhold I.J., et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 334 8 (1996) 507-512
21. Laue L., Wu S.M., Kudo M., et al. A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Hum Mol Genet 4 8 (1995) 1429-1433
22. Kremer H., Kraaij R., Toledo S.P., et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 9 2 (1995) 160-164
23. Phillip M., Arbelle J.E., Segev Y., et al. Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone. N Engl J Med 338 24 (1998) 1729-1732
24. Aittomaki K., Lucena J.L., Pakarinen P., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82 6 (1995) 959-968
25. McLachlan R.I., O'Donnell L., Meachem S.J., et al. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl 23 2 (2002) 149-162
26. Turner T.T., Jones C.E., Howards S.S., et al. On the androgen microenvironment of maturing spermatozoa. Endocrinology 115 5 (1984) 1925-1932
27. Singh J., O'Neill C., and Handelsman D.J. Induction of spermatogenesis by androgens in gonadotropin-deficient (HPG) mice. Endocrinology 136 12 (1995) 5311-5321
28. Cabrera M.S., Vogiatzi M.G., and New M.I. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 86 7 (2001) 3070-3078
29. Urban M.D., Lee P.A., and Migeon C.J. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 299 25 (1978) 1392-1396
30. Quigley C.A., De Bellis A., Marschke K.B., et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16 3 (1995) 271-321
31. Balducci R., Ghirri P., Brown T.R., et al. A clinician looks at androgen resistance. Steroids 61 4 (1996) 205-211
32. Yong E.L., Loy C.J., and Sim K.S. Androgen receptor gene and male infertility. Hum Reprod Update 9 1 (2003) 1-7
33. Yong E.L., Tut T.G., Ghadessy F.J., et al. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain. Mol Cell Endocrinol 137 1 (1998) 41-50
34. Ghadessy F.J., Lim J., Abdullah A.A., et al. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions. J Clin Invest 103 11 (1999) 1517-1525
35. Ong Y.C., Kolatkar P.R., and Yong E.L. Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in Helix 8-Helix 10 interactions and in receptor ligand-binding domain stability. Mol Hum Reprod 8 2 (2002) 101-108
36. Yong E.L., Lim L.S., Wang Q., et al. Androgen receptor polymorphisms and mutations in male infertility. J Endocrinol Invest 23 9 (2000) 573-577
37. Loy C.J., and Yong E.L. Sex, infertility and the molecular biology of the androgen receptor. Curr Opin Obstet Gynecol 13 3 (2001) 315-321
38. Balducci R., Adamo M.V., Mangiantini A., et al. Testicular responsiveness to a single hCG dose in patients with testicular feminization. Horm Metab Res 21 8 (1989) 449-452
39. Campo S., Stivel M., Nicolau G., et al. Testicular function in post pubertal male pseudohermaphroditism. Clin Endocrinol (Oxf) 11 5 (1979) 481-490
40. Aono T., Miyake A., Kinugasa T., et al. Absence of positive feedback effect of oestrogen on LH release in patients with testicular feminization syndrome. Acta Endocrinol (Copenh) 87 2 (1978) 259-267
41. Cicognani A., Cacciari E., Tacconi M., et al. Effect of gonadectomy on growth hormone, IGF-I and sex steroids in children with complete and incomplete androgen insensitivity. Acta Endocrinol (Copenh) 121 6 (1989) 777-783
42. Jarow J.P. Endocrine causes of male infertility. Urol Clin North Am 30 1 (2003) 83-90
43. De Kretser D.M., O'Bryan M.K., Cram D., et al. Expanding our understanding of spermatogenesis: the future genetic tests for infertility. Int J Androl 23 Suppl 2 (2000) 30-33
44. Lilford R., Jones A.M., Bishop D.T., et al. Case-control study of whether subfertility in men is familial. Bmj 309 6954 (1994) 570-573
45. Siddiq F.M., and Sigman M. A new look at the medical management of infertility. Urol Clin North Am 29 4 (2002) 949-963
46. Collins J.A., Wrixon W., Janes L.B., et al. Treatment-independent pregnancy among infertile couples. N Engl J Med 309 20 (1983) 1201-1206
47. Badenoch D.F., Waxman J., Boorman L., et al. Administration of a gonadotropin releasing hormone analogue in oligozoospermic infertile males. Acta Endocrinol (Copenh) 117 2 (1988) 265-267
48. Bals-Pratsch M., Knuth U.A., Honigl W., et al. Pulsatile GnRH-therapy in oligozoospermic men does not improve seminal parameters despite decreased FSH levels. Clin Endocrinol (Oxf) 30 5 (1989) 549-560
49. Crottaz B., Senn A., Reymond M.J., et al. Follicle-stimulating hormone bioactivity in idiopathic normogonadotropic oligoasthenozoospermia: double-blind trial with gonadotropin-releasing hormone. Fertil Steril 57 5 (1992) 1034-1043
50. Matsumiya K., Kitamura M., Kishikawa H., et al. A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia. Int J Urol 5 4 (1998) 361-363
51. Schwarzstein L., Aparicio N.J., Turner D., et al. Use of synthetic luteinizing hormone-releasing hormone in treatment of oligospermic men: a preliminary report. Fertil Steril 26 4 (1975) 331-336
52. Aparicio N.J., Schwarzstein L., Turner E.A., et al. Treatment of idiopathic normogonadotropic oligoasthenospermia with synthetic luteinizing hormone-releasing hormone. Fertil Steril 27 5 (1976) 549-555
53. Schwarzstein L., Aparicio N.J., and Schally A.V. D-tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia. Int J Androl 5 2 (1982) 171-178
54. Fauser B.C., Rolland R., Dony J.M., et al. Long-term, pulsatile, low dose, subcutaneous luteinizing hormone-releasing hormone administration in men with idiopathic oligozoospermia. Failure of therapeutic and hormonal response. Andrologia 17 2 (1985) 143-149
55. Honigl W., Knuth U.A., and Nieschlag E. Selective reduction of elevated FSH levels in infertile men by pulsatile LHRH treatment. Clin Endocrinol (Oxf) 24 2 (1986) 177-182
56. Aulitzky W., Frick J., and Hadziselimovic F. Pulsatile LHRH therapy in patients with oligozoospermia and disturbed LH pulsatility. Int J Androl 12 4 (1989) 265-272
57. Moudgal N.R., Murthy G.S., Prasanna Kumar K.M., et al. Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. Hum Reprod 12 3 (1997) 457-463
58. Attia A.M., Al-Inany H.G., and Proctor M.L. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 1 (2006) CD005071
59. Knuth U.A., Honigl W., Bals-Pratsch M., et al. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J Clin Endocrinol Metab 65 6 (1987) 1081-1087
60. Kamischke A., Behre H.M., Bergmann M., et al. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod 13 3 (1998) 596-603
61. Foresta C., Bettella A., Garolla A., et al. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 84 3 (2005) 654-661
62. Baccetti B., Piomboni P., Bruni E., et al. Effect of follicle-stimulating hormone on sperm quality and pregnancy rate. Asian J Androl 6 2 (2004) 133-137
63. Ashkenazi J., Bar-Hava I., Farhi J., et al. The role of purified follicle stimulating hormone therapy in the male partner before intracytoplasmic sperm injection. Fertil Steril 72 4 (1999) 670-673
64. Wang C., Chan C.W., Wong K.K., et al. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 40 3 (1983) 358-365
65. Pusch H.H. Oral treatment of oligozoospermia with testosterone-undecanoate: results of a double-blind-placebo-controlled trial. Andrologia 21 1 (1989) 76-82
66. Comhaire F. Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 54 4 (1990) 689-693
67. Gregoriou O., Papadias C., Gargaropoulos A., et al. Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Obstet Gynecol 20 1 (1993) 9-12
68. Comhaire F., Schoonjans F., Abdelmassih R., et al. Does treatment with testosterone undecanoate improve the in-vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (results of a double blind study). Hum Reprod 10 10 (1995) 2600-2602
69. Adamopoulos D.A., Pappa A., Billa E., et al. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 80 4 (2003) 914-920
70. Mauss J. Results of treatment of male fertility disorders with mesterolone or a placebo. Arzneimittelforschung 24 9 (1974) 1338-1341 [in German]
71. Aafjes J.H., van der Vijver J.C., Brugman F.W., et al. Double-blind cross over treatment with mesterolone and placebo of subfertile oligozoospermic men value of testicular biopsy. Andrologia 15 Spec No (1983) 531-535
72. Hargreave T.B., Kyle K.F., Baxby K., et al. Randomised trial of mesterolone versus vitamin C for male infertility. Scottish Infertility Group. Br J Urol 56 6 (1984) 740-744
73. Mesterolone and idiopathic male infertility: a double-blind study. World Health Organization Task Force on the Diagnosis and Treatment of Infertility. Int J Androl 12 4 (1989) 254-264
74. Gerris J., Comhaire F., Hellemans P., et al. Placebo-controlled trial of high-dose mesterolone treatment of idiopathic male infertility. Fertil Steril 55 3 (1991) 603-607
75. Liu P.Y., and Handelsman D.J. The present and future state of hormonal treatment for male infertility. Hum Reprod Update 9 1 (2003) 9-23
76. Kamischke A., and Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod 14 Suppl 1 (1999) 1-23
77. O'Donovan P.A., Vandekerckhove P., Lilford R.J., et al. Treatment of male infertility: is it effective? Review and meta-analyses of published randomized controlled trials. Hum Reprod 8 8 (1993) 1209-1222
78. Abel B.J., Carswell G., Elton R., et al. Randomised trial of clomiphene citrate treatment and vitamin C for male infertility. Br J Urol 54 6 (1982) 780-784
79. Sokol R.Z., Steiner B.S., Bustillo M., et al. A controlled comparison of the efficacy of clomiphene citrate in male infertility. Fertil Steril 49 5 (1988) 865-870
80. A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization. Int J Androl 15 4 (1992) 299-307
81. Ronnberg L. The effect of clomiphene citrate on different sperm parameters and serum hormone levels in preselected infertile men: a controlled double-blind cross-over study. Int J Androl 3 5 (1980) 479-486
82. Micic S., and Dotlic R. Evaluation of sperm parameters in clinical trial with clomiphene citrate of oligospermic men. J Urol 133 2 (1985) 221-222
83. Hussein A., Ozgok Y., Ross L., et al. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl 26 6 (2005) 787-791 [discussion: 792-3]
84. Torok L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). Andrologia 17 5 (1985) 497-501
85. AinMelk Y., Belisle S., Carmel M., et al. Tamoxifen citrate therapy in male infertility. Fertil Steril 48 1 (1987) 113-117
86. Krause W., Holland-Moritz H., and Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen-a randomized controlled study. Int J Androl 15 1 (1992) 14-18
87. Vandekerckhove P., Lilford R., Vail A., et al. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2 (2000) CD000151
88. Inkster S., Yue W., and Brodie A. Human testicular aromatase: immunocytochemical and biochemical studies. J Clin Endocrinol Metab 80 6 (1995) 1941-1947
89. Pavlovich C.P., King P., Goldstein M., et al. Evidence of a treatable endocrinopathy in infertile men. J Urol 165 3 (2001) 837-841
90. Kulin H.E., and Reiter E.O. Gonadotropin suppression by low dose estrogen in men: evidence for differential effects upon FSH and LH. J Clin Endocrinol Metab 35 6 (1972) 836-839
91. Ciaccio L.A., Joseph A.A., and Kincl F.A. Direct inhibition of testicular function in rats by estriol and progesterone. J Steroid Biochem 9 12 (1978) 1257-1259
92. Jones T.M., Fang V.S., Landau R.L., et al. Direct inhibition of Leydig cell function by estradiol. J Clin Endocrinol Metab 47 6 (1978) 1368-1373
93. Robertson K.M., O'Donnell L., Jones M.E., et al. Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proc Natl Acad Sci U S A 96 14 (1999) 7986-7991
94. Raman J.D., and Schlegel P.N. Aromatase inhibitors for male infertility. J Urol 167 2 Pt 1 (2002) 624-629
95. Clark R.V., and Sherins R.J. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 10 3 (1989) 240-247
96. Thackare H., Nicholson H.D., and Whittington K. Oxytocin-its role in male reproduction and new potential therapeutic uses. Hum Reprod Update 12 4 (2006) 437-448
97. Ogawa S., Kudo S., Kitsunai Y., et al. Increase in oxytocin secretion at ejaculation in male. Clin Endocrinol (Oxf) 13 1 (1980) 95-97
98. Filippi S., Vannelli G.B., Granchi S., et al. Identification, localization and functional activity of oxytocin receptors in epididymis. Mol Cell Endocrinol 193 1-2 (2002) 89-100
99. Nicholson H.D., Guldenaar S.E., Boer G.J., et al. Testicular oxytocin: effects of intratesticular oxytocin in the rat. J Endocrinol 130 2 (1991) 231-238
100. Byrne M.M., Rolf C., Depenbusch M., et al. Lack of effect of a single i.v. dose of oxytocin on sperm output in severely oligozoospermic men. Hum Reprod 18 10 (2003) 2098-2102
101. Kogan S.J. Fertility in cryptorchidism. An overview in 1987. Eur J Pediatr 146 Suppl 2 (1987) S21-S24
102. Cortes D., Thorup J.M., and Lindenberg S. Fertility potential after unilateral orchiopexy: an age independent risk of subsequent infertility when biopsies at surgery lack germ cells. J Urol 156 1 (1996) 217-220
103. Job J.C., Gendrel D., Safar A., et al. Pituitary LH and FSH and testosterone secretion in infants with undescended testes. Acta Endocrinol (Copenh) 85 3 (1977) 644-649
104. Gendrel D., Job J.C., and Roger M. Reduced post-natal rise of testosterone in plasma of cryptorchid infants. Acta Endocrinol (Copenh) 89 2 (1978) 372-378
105. Baker B.A., Morley R., and Lucas A. Plasma testosterone in preterm infants with cryptorchidism. Arch Dis Child 63 10 (1988) 1198-1200
106. Huff D.S., Hadziselimovic F., Snyder III H.M., et al. Postnatal testicular maldevelopment in unilateral cryptorchidism. J Urol 142 2 Pt 2 (1989) 546-548 [discussion: 572]
107. Huff D.S., Hadziselimovic F., Snyder III H.M., et al. Histologic maldevelopment of unilaterally cryptorchid testes and their descended partners. Eur J Pediatr 152 Suppl 2 (1993) S11-S14
108. Hadziselimovic F., and Herzog B. Treatment with a luteinizing hormone-releasing hormone analogue after successful orchiopexy markedly improves the chance of fertility later in life. J Urol 158 3 Pt 2 (1997) 1193-1195
109. Huff D.S., Snyder III H.M., Rusnack S.L., et al. Hormonal therapy for the subfertility of cryptorchidism. Horm Res 55 1 (2001) 38-40
110. Ries L.A.G., Eisner M.P., Kosary C.L., et al. SEER Cancer Statistics Review, 1975-2000. Available at:. http://seer.cancer.gov/csr/1975_2000/ Accessed July 30, 2007
111. Shetty G., and Meistrich M.L. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J Natl Cancer Inst Monogr 34 (2005) 36-39
112. Howell S.J., Radford J.A., Ryder W.D., et al. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 17 5 (1999) 1493-1498
113. Brennemann W., Stoffel-Wagner B., Helmers A., et al. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158 3 Pt 1 (1997) 844-850
114. Kangasniemi M., Huhtaniemi I., and Meistrich M.L. Failure of spermatogenesis to recover despite the presence of a spermatogonia in the irradiated LBNF1 rat. Biol Reprod 54 6 (1996) 1200-1208
115. Meistrich M.L., Wilson G., and Huhtaniemi I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Cancer Res 59 15 (1999) 3557-3560
116. Shuttlesworth G.A., de Rooij D.G., Huhtaniemi I., et al. Enhancement of A spermatogonial proliferation and differentiation in irradiated rats by gonadotropin-releasing hormone antagonist administration. Endocrinology 141 1 (2000) 37-49
117. Meistrich M.L., and Kangasniemi M. Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia. J Androl 18 1 (1997) 80-87
118. Meistrich M.L., Wilson G., Shuttlesworth G., et al. GnRH agonists and antagonists stimulate recovery of fertility in irradiated LBNF1 rats. J Androl 22 5 (2001) 809-817
119. Kurdoglu B., Wilson G., Parchuri N., et al. Protection from radiation-induced damage to spermatogenesis by hormone treatment. Radiat Res 139 1 (1994) 97-102
120. Parchuri N., Wilson G., and Meistrich M.L. Protection by gonadal steroid hormones against procarbazine-induced damage to spermatogenic function in LBNF1 hybrid rats. J Androl 14 4 (1993) 257-266
121. Masala A., Faedda R., Alagna S., et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126 4 (1997) 292-295
122. Johnson D.H., Linde R., Hainsworth J.D., et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 65 4 (1985) 832-836
123. Waxman J.H., Ahmed R., Smith D., et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19 2 (1987) 159-162
124. Redman JR, Bajorunas DR. Suppression of germ cell proliferation to prevent gonadal toxicity associated with cancer treatment. Workshop on Psychosexual and Reproductive Issues Affecting Patients with Cancer. New York; 1987. p. 90-4.
125. Fossa S.D., Klepp O., and Norman N. Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. Br J Urol 62 5 (1988) 449-453
126. Kreuser E.D., Hetzel W.D., Hautmann R., et al. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 22 9 (1990) 494-498
127. Brennemann W., Brensing K.A., Leipner N., et al. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-tryptophan-6 luteinizing hormone releasing hormone. Clin Investig 72 11 (1994) 838-842
128. Radford J. Restoration of fertility after treatment for cancer. Horm Res 59 Suppl 1 (2003) 21-23
129. Ogawa T., Dobrinski I., Avarbock M.R., et al. Leuprolide, a gonadotropin-releasing hormone agonist, enhances colonization after spermatogonial transplantation into mouse testes. Tissue Cell 30 5 (1998) 583-588
130. Dobrinski I., Ogawa T., Avarbock M.R., et al. Effect of the GnRH-agonist leuprolide on colonization of recipient testes by donor spermatogonial stem cells after transplantation in mice. Tissue Cell 33 2 (2001) 200-207